Longevity
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal
Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases
Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases
Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration